73 / 86
TABLE 1. Botulinum Toxin Manufacturer Recommendations on Supply, Dilution, and Storage
OnabotulinumtoxinA AbobotulinumtoxinA BONTA
BONTA
IncobotulinumtoxinA RimabotulinumtoxinB
Company
Allergan, Inc.
Ipsen Inc./Medicis
Inc.
Lanzhou
Medy-Tox Inc.,
South Korea
Merz Pharmaceuti-
cals
Solstice Neuro-
sciences Inc./Eisai
Co., Ltd.
Commercial
names
Botox, Botox cos
metic, Vistabel,
Vistabex
Dysport, Reloxin,
Azzalure
Prosigne
Lantox, Redux
Neuronox,
Meditoxin
Botulift
Xeomin, Bocoture
Myobloc, Neurobloc
Approvals
Worldwide, includ-
ing United States
and Canada
In more than 65
countries, includ-
ing United States
and Canada
4
10 countries
including China
Korea, India,
Latin South
America
Germany, other
European coun-
tries, Mexico,
Argentina, Brazil
United States, some
European coun-
tries
Type
Type A-Hall strain Type A (NCTC 2916
strain)
A
A
Type A-Hall strain B
Active sub-
stance
Botulinum toxin type
A complex
(900 kDa)
Botulinum toxin
type A complex
(400 kDa)
Botulinum toxin
type A
(900 kDa)
y
Botulinum
toxin type A
(940 kDa)
Botulinum toxin
type A, free from
complexing pro-
teins (150 kDa)
Botulinum toxin type
B (700 kDa)
Indications
Blepharospasm,
cervical dystonia,
glabellar lines,
hyperhidrosis,
chronic migraine
Blepharospasm,
cervical dystonia,
glabellar lines
Blepharospasm,
cervical dysto-
nia, glabellar
lines, hyper-
hidrosis
Blepharospasm Blepharospasm,
cervical dystonia,
cosmetic use in
some countries
Cervical dystonia
Mode of action SNAP 25/SV2
SNAP 25/SV2
SNAP 25
SNAP 25
SNAP 25
Vesicle associated
membrane protein
U/vial
100 or 200
300 or 500
100 or 50
100
100 or 50
2,500, 5,000, or
10,000
Pharmaceutical
form
Powder dissolved in
solution for injec-
tion
Powder dissolved in
solution for injec-
tion
Powder dis-
solved in solu-
tion for
injection
Powder dis-
solved in
solution for
injection
Powder dissolved in
solution for injec-
tion
Solution
Excipients
500
m
g HSA
0.9mg NaCl
125
m
g HSA
2.5mg lactose
5mg gelatin
25mg dextran
25mg sucrose
500
m
g HSA
0.9mg NaCl
1,000
m
g HSA
4.7mg sucrose
500
m
g/mL HSA
NaCl 0.1M
Disodium succinate
0.01MHCl (to adjust
pH)
Water for injection
Transportation
and storage
before dilu-
tion
2–8
1
C
2–8
1
C
2–8
1
C
2–8
1
C
o
25
1
C
2–8
1
C
3 7 : 1 1 : NOVEMBER 2 0 1 1
TR I NDADE DE ALME I DA ET AL